Sentences with phrase «medicine company developing»

Novo Biosciences based of Bar Harbor, Maine is a regenerative medicine company developing small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

Cynata Therapeutics Limited is an Australian clinical - stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus ™ stem cell technology platform.

Not exact matches

A crop of young biotech companies is sprouting up to develop medicines.

So many companies have developed such increasingly effective medicines, such as those that treat more hep C strains with far shorter treatment regimens, that Gilead — a pioneer in the field with Sovaldi and Harvoni — is projecting $ 3.5 billion to $ 4 billion in U.S. sales from these kinds of drugs in 2018, a dramatic drop from nearly $ 13 billion in 2015.

About Alkermes plc Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.

Some has gone to companies like Twist Bioscience, a San Francisco company developing a proprietary synthetic DNA manufacturing process to aid in diagnostics and the production of personalized medicines and sustainable chemicals.

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

That will then form a starting point for companies and researchers to develop precision medicines that can target these diseases and determine which patients may respond best to existing or new medicines, reported the Wall Street Journal.

Over the past three decades, the Tufts Center for the Study of Drug Development has estimated both the cost and the years it takes for companies to develop new medicines.

The clinical - stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life - altering central nervous system (CNS) disorders, SAGE Therapeutics Inc. (NASDAQ: SAGE) seem to be poised for a price surge as per its latest charts.

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

But this week, a rival drug company has announced that they were able to develop a cheaper alternative version of the medicine, and it's only going to cost patients $ 1.

In medicine today, physician - scientists and basic scientists supplement support for their research by applying their expertise part time to develop and test commercial products.1 In my own field, vision science, university - based researchers obtain additional funding through clinical and electrophysiologic studies, pathology, imaging, biochemistry, and animal model development performed for pharmaceutical and instrument companies.

The technology has been licensed to Cambridge spin - out company TeraView, who are developing it for use in the pharmaceutical industry in order to make medicines that are more easily released in the body.

Researchers from the Singapore - MIT Alliance for Research and Technology (SMART), DukeNUS Graduate School of Medicine (Duke - NUS), National University of Singapore (NUS) and Nanyang Technological University (NTU) have collaborated with the Massachusetts Institute of Technology (MIT) and a biotechnology company, Visterra, to develop a single treatment.

GSK says it also plans to take a more «graduated» approach to filing and enforcing patents for other medicines to encourage generic drug companies to make and supply GSK products now available mainly in developed countries.

Not all of the job offers come from companies looking to develop medicine.

Counterfeit drugs are estimated to make up as much as 30 % of medicines in some developing countries and cost legitimate pharmaceutical companies up to $ 200 billion per year.

Kazuyoshi Maejima of the School of Medicine at Keio University in Tokyo led a team of academics that developed the Koken rat jointly with company researchers.

Hoping to cash in on personalized cancer therapy, a new company called Foundation Medicine — founded in part by genome guru Eric Lander of the Broad Institute — plans to develop tests for genetic glitches in tumors that make them vulnerable to specific drugs, reports the United Kingdom's Times Online.

These systems were developed by Epharmix, a health care information technology startup company founded by students from Washington University School of Medicine.

Founded on the principle that strong science would lead to important new medicines, Regeneron has become an integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.

In Texas the Ebola patient is now stable but in critical condition and being treated with brincidofovir, an oral medicine developed by Durham, N.C. — based biopharmaceutical company, Chimerix.

Founded on the principle that strong science would lead to important new medicines, Regeneron has become an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions.

The first anti-EGFR antibody (cetuximab) for cancer treatment in human medicine was developed by the company Merck.

A few programs serve science graduates who want to go into toxicology; UW, for example, just launched a certificate program in biologics safety to teach basic toxicology to scientists working at biotechnology companies that develop protein and other medicines based on large molecules.

One of the core beliefs at ISB is that medicine will become more and more personalized, with people sequencing their own genes and pharmaceutical companies developing drugs for groups with certain genetic characteristics.

«Asimov's laws are about as relevant to robotics as leeches are to modern medicine,» says Steve Grand, who founded the UK company Cyberlife Research and is working on developing artificial intelligence through learning.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs.

He is the co-founder of Abel Therapeutics LLC, a start up company that is researching, developing, and commercializing the first and only preventative medicine for treating Clostridium difficile, one of the fastest growing epidemics in the U.S. C - diff spores can be contracted anytime a patient is in a hospital, nursing home, surgery center, or other similar facility.

Several biotechnology companies are using the gene editing technique in an effort to develop therapies for treating genetic diseases, including CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.

GigaGen is a fast - growing biopharmaceutical company with a mission to make a difference in the way life - changing medicines are discovered and developed.

She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with three partnered Phase II clinical programs and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine, Dr. Leahy has more than 25 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning.

Other Institutions also belong to the Campus: the University of Milan; Cogentech, an IFOM - IEO consortium committed to developing leading genomic technologies (nanotechnologies, proteomics, bioinformatics, disease models), the European School of Molecular Medicine (SEMM), that organizes training in emerging sectors of Biomedicine, offering the first European PhDs in Molecular Medicine, Medical Nanotechnologies, Foundations of the Life Sciences and their Ethical Consequences; Genextra, a biotech company whose mission is to develop new therapies against cancer and aging - related disease; Biopolo, a not for profit company involved in the technological transfer of basic research to the productive system.

ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes.

San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty fcompany focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty fCompany was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign.

BIIB054 was originally developed by biotech company Neurimmune, using a platform they call Reverse Translational Medicine (RTM ®), which derives therapeutic antibody candidates from libraries of de-identified B - cells isolated from ostensibly healthy older adults (those free of specific neurological diseases of aging).

Gosselies, Belgium — February 9, 2018 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs in two oral presentations at the upcoming Molecular Medicine Tri-Conference 2018, taking place from February 11 - 16, 2018 in San Francisco, CA.

ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

She also helped develop the company's tailored therapeutics and personalized medicine strategy.

Regeneron — a company that develops and produces medicines for diseases such as asthma and cancer — became the competition's sponsor last year.

SAN DIEGO and SAN FRANCISCO, February 23, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, and Beyond Type 1, a not - for - profit advocacy and education group for those living with type 1 diabetes, today announced a grant from Beyond Type 1 to support ViaCyte's efforts to develop a functional cure for type 1 and other insulin - requiring diabetes.

A2 Biotherapeutics is an early - stage biotechnology company located in Southern California that develops novel medicines for serious illnesses.

ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self - renewal properties of the body through specific control of the Wnt signaling pathway.

July 1, 2015 UChicago Medicine, Little Company of Mary expand pediatric partnership: Affiliation to boost community access to specialty care for infants and children The University of Chicago Medicine and Little Company of Mary Hospital and Health Care Centers are partnering to expand care for infants and children by developing a subspecialty center on the community hospital's Evergreen Park campus that will provide enhanced neonatology and pediatric services.

With his company, Advanced BioCell, Mr. Quateman has developed a comprehensive process for engaging, guiding and educating and servicing clients in the rapidly growing field of systems - based personalized functional medicine, the leading edge of the wellness industry.